

# Ewa Lech-Maranda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2199224/publications.pdf>

Version: 2024-02-01

156  
papers

4,463  
citations

185998

28  
h-index

110170

64  
g-index

157  
all docs

157  
docs citations

157  
times ranked

6421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	0.6	8
2	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. <i>Oncogene</i> , 2022, 41, 1600-1609.	2.6	9
3	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
4	Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma - Real World Report of Polish Lymphoma Research Group. <i>Chemotherapy</i> , 2022, , .	0.8	0
5	Hematological malignancies in Polish population: what are the predictors of outcome in patients admitted to Intensive Care Unit?. <i>Supportive Care in Cancer</i> , 2021, 29, 323-330.	1.0	7
6	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	5.1	46
7	Trudności w leczeniu chorego na ostrą, białą, czarną szpikową z mutacją FLT3-ITD i wysokim stosunkiem allelicznym oporność na standardową chemioterapię indukującą w późnym leczeniu z midostauryną. <i>Hematologia</i> , 2021, 11, 253-258.		
8	Konsensus ekspertów w Polskiej Grupy Badawczej Chłoniaka w zakresie postępowania w nawrotowym lub opornym na leczenie klasycznym chłoniakiem Hodgkina w 2020 roku. <i>Hematologia</i> , 2021, 11, 193-211.	0.0	1
9	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	6.3	260
10	Umbralisib, a Dual PI3K/CK1 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
11	The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2683.	1.0	4
12	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e410-e421.	2.2	83
13	Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG). <i>Cancers</i> , 2021, 13, 4189.	1.7	6
14	Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	2.5	13
15	Current status and achievements of Polish haemato-oncology. <i>Acta Haematologica Polonica</i> , 2021, 52, 4-17.	0.1	6
16	Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations. <i>Acta Haematologica Polonica</i> , 2021, 52, 528-542.	0.1	1
17	Outcomes of treatment with dose-adjusted EPOCH or R-CHOP in primary mediastinal large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 59-66.	1.1	25
18	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	0.5	8
20	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <i>Advances in Medical Sciences</i> , 2020, 65, 371-377.	0.9	2
21	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. <i>Cell Death and Disease</i> , 2020, 11, 956.	2.7	20
22	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2020, 61, 1748-1751.	0.6	2
23	Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group. <i>Archives of Medical Science</i> , 2020, 16, 157-161.	0.4	1
24	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
25	Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group. <i>Acta Haematologica Polonica</i> , 2020, 51, 60-72.	0.1	0
26	Zdaniem konsultanta. <i>Hematologia</i> , 2020, 10, 199-200.	0.0	0
27	Wentoklaks w monoterapii przewlekłej, ciężkiej limfocytowej przedśrótnym przeszczepieniem allogenicznym krwiotwórczych komórek macierzystych. <i>Hematologia</i> , 2020, 11, 95-100.	0.0	0
28	PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium. <i>Blood</i> , 2020, 136, 16-17.	0.6	1
29	Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 195-202.	0.6	22
30	Hematological Malignancies in the Polish Population: What are the Predictors of Outcome in Patients Admitted to Intensive Care Unit?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S219.	0.2	0
31	Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. <i>Molecular Oncology</i> , 2019, 13, 1180-1195.	2.1	24
32	Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development. <i>International Journal of Molecular Sciences</i> , 2019, 20, 843.	1.8	26
33	Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6048.	1.8	5
34	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. <i>Leukemia and Lymphoma</i> , 2019, 60, 1409-1419.	0.6	0
35	Inhibition of thioredoxin-dependent H <sub>2</sub> O <sub>2</sub> removal sensitizes malignant B-cells to pharmacological ascorbate. <i>Redox Biology</i> , 2019, 21, 101062.	3.9	29
36	Primary and Secondary Central Nervous System Involvement in Acute Myeloid Leukemia. , 2019, 07, .		6

#	ARTICLE	IF	CITATIONS
37	Zdaniem konsultanta. <i>Hematologia</i> , 2019, 9, 342-343.	0.0	0
38	Abstract CT132: Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study. , 2019, , .		0
39	Stosowanie lek <sup>3</sup> w biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematolog <sup>3</sup> w i Transfuzjolog <sup>3</sup> w. <i>Acta Haematologica Polonica</i> , 2019, 50, 51-56.	0.1	0
40	Rola brentuksymabu vedotin w leczeniu chorych na opornego/nawrotowego ch <sup>4</sup> oniaka Hodgkina na przyk <sup>4</sup> adzie dw <sup>3</sup> ch opis <sup>3</sup> w przypadk <sup>3</sup> w. <i>Hematologia</i> , 2019, 10, 7-16.	0.0	0
41	High Activity of Cladribine (2-CdA) Combined with Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Azacitidine Failure. <i>Blood</i> , 2019, 134, 1360-1360.	0.6	1
42	Characteristics and Outcomes of Patients with Lymphoma Who Developed Therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome - a Retrospective Analysis of the Polish Adult Leukemia Group. <i>Blood</i> , 2019, 134, 5422-5422.	0.6	0
43	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019, 134, 4026-4026.	0.6	0
44	Profilaktyka reaktywacji zaka <sup>4</sup> 1/4e <sup>4</sup> , HBV – rekomendacje grupy roboczej profilaktyki reaktywacji HBV. <i>Acta Haematologica Polonica</i> , 2019, 50, 192-198.	0.1	0
45	Microenvironment <sup>4</sup> induced PIM kinases promote CXCR 4 <sup>4</sup> triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3548-3559.	1.6	17
46	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. <i>Oncolmmunology</i> , 2018, 7, e1423183.	2.1	23
47	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin <sup>4</sup> ™s Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
48	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 16917-16931.	0.8	25
49	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018, 2, 1522-1531.	2.5	33
50	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case <sup>4</sup> control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	2.0	6
51	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a <sup>4</sup> real <sup>4</sup> world <sup>4</sup> study: Polish Myeloma Group experience. <i>European Journal of Haematology</i> , 2018, 101, 354-361.	1.1	13
52	Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab <sup>4</sup> associated anaphylaxis. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 494-495.	0.3	3
53	Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). <i>Anticancer Research</i> , 2018, 38, 3025-3030.	0.5	7
54	Zalecenia Polskiej Grupy Szpiczakowej dotycz <sup>4</sup> ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.1	4

#	ARTICLE	IF	CITATIONS
55	Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies. , 2018, , .		0
56	Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial. Blood, 2018, 132, 3151-3151.	0.6	0
57	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	13.9	1,443
58	Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Medical Oncology, 2017, 34, 104.	1.2	35
59	Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 176, 618-628.	1.2	36
60	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	0.6	40
61	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma. International Journal of Hematology, 2017, 106, 794-800.	0.7	6
62	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.1	5
63	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma â€“ Polish retrospective multicenter analysis. Polish Archives of Internal Medicine, 2017, 127, 765-774.	0.3	7
64	Rola idelalizybu w leczeniu chorych na przewlekÄ... biaÄ,aczkÄ™ limfocytowÄ... Hematologia, 2017, 7, 217-230.o.o		1
65	Limfocytarne zapalenie opon mÄ³zgowo-rdzeniowych w przebiegu dokanaÄ,owego leczenia liposomalnÄ... cytarabinÄ... u chorego na ostrÄ... biaÄ,aczkÄ™ limfoblastycznÄ... Hematologia, 2017, 8, 228-233.	0.0	1
66	Instytut Hematologii i Transfuzjologii â€” nowatorskie rozwiÄ...zania polegajÄ...ce na kompleksowoÄci, koordynacji, innowacyjnoÄci i jakoÄci w celu poprawy diagnostyki i leczenia, komfortu chorego i postÄ™pu w medycynie. Hematologia, 2017, 7, 173-216.	0.0	0
67	Przeszczepienie krwiotwÄ³rczych komÄ³rek macierzystych w nawrotowej wtÄ³rnej limfohistiocytocie hemofagocytarnej. Hematologia, 2017, 7, 327-338.	0.0	0
68	Blinatumomab â€” nowy lek u chorych na nawrotowÄ... /opornÄ... ostrÄ... biaÄ,aczkÄ™ limfoblastycznÄ... Hematologia, 2017, 7, 312-326.	0.0	1
69	Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r) Tj ETQq1 1 @.784314 ogBT /Ov		
70	Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies. , 2017, , .		0
71	WspÄ³Ä,istnienie dyskrazji komÄ³rek plazmatycznych i zespoÄ,u mielodysplastycznego â€” opisy przypadkÄ³w i przeglÄ...d piÄmiennictwa. Hematologia, 2017, 8, 144-151.	0.0	2
72	ZachorowalnoÄ¶ i chorobowoÄ¶ na nowotwory ukÄ,adu krwiotwÄ³rczego w Polsce (2009â€“2015) okreÅlone na podstawie analizy danych Narodowego Funduszu Zdrowia wykorzystanych w projekcie â€”Mapy potrzeb zdrowotnych â€” baza analiz systemowych i wdroÅ¼eniowychâ€• Hematologia, 2017, 8, 89-104.	0.0	0

#	ARTICLE	IF	CITATIONS
73	Ocena stanu odżywienia pacjentów z nowotworami układowymi w krwiotwórczego i chłonnego za pomocą skali PG-SGA. <i>Hematologia</i> , 2017, 8, 105-112.	0.0	0
74	Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in <i>DNA methyltransferase 3A</i> and <i>isocitrate dehydrogenase 1 and 2</i> genes in acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2016, 96, 181-187.	1.1	14
75	Intragenic Variations in <i>BTLA</i> Gene Influence mRNA Expression of <i>BTLA</i> Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 137-145.	1.0	21
76	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	1.0	12
77	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 739-748.	0.6	54
78	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.1	10
79	Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients – Report of the Polish Myeloma Group. <i>Leukemia Research</i> , 2016, 40, 90-99.	0.4	3
80	Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease. <i>Leukemia and Lymphoma</i> , 2016, 57, 1471-1473.	0.6	1
81	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	0.6	1
82	Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. <i>Blood</i> , 2016, 128, 3239-3239.	0.6	4
83	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	1.1	26
84	Niedoczynność przysadki u chorego na chłoniaka Hodgkina. <i>Hematologia</i> , 2016, 7, 161-166.	0.0	1
85	Skuteczność lenalidomidu u chorego na szpiczaka plazmocytoowego współistniejącego z zespołem mielodysplastycznym związanym z izolowaną delecją chromosomu 5q. <i>Hematologia</i> , 2016, 7, 77-84.	0.0	0
86	Zachorowalność i umieralność u chorych na przewlekłą białaczkę limfocytową w Polsce w latach 1999-2013. <i>Hematologia</i> , 2016, 7, 108-116.	0.0	0
87	Human leukocyte antigen <i>G</i> polymorphisms influence the clinical outcome in diffuse large <i>B</i> -cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 185-193.	1.5	18
88	Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. <i>Blood Cancer Journal</i> , 2015, 5, e300-e300.	2.8	4
89	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2331-2338.	0.6	9
90	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytoowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.1	0

#	ARTICLE	IF	CITATIONS
91	High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3348-3356.	0.6	5
92	Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q). <i>BMC Cancer</i> , 2015, 15, 508.	1.1	5
93	Circulating CD4 <sup>+</sup> CXCR5 <sup>+</sup> T Cells Exacerbate B Cell Antibody Production in Crohn's Disease Through IL-21 Secretion. <i>Immunological Investigations</i> , 2015, 44, 665-677.	1.0	3
94	Postępy w diagnostyce i leczeniu chorych na chłoniaki nie-Hodgkina. <i>Hematologia</i> , 2015, 6, 31-43.	0.0	2
95	Postępy w diagnostyce i leczeniu chorych na przewlekłą, białą, czerną limfocytową... <i>Hematologia</i> , 2015, 6, 1980.	0.0	0
96	Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. <i>Cancer Research</i> , 2015, 75, 5394-5394.	0.4	1
97	Wyzwania systemowe stojące przed hematologią onkologiczną w aspekcie starzejącego się społeczeństwa w Polsce. <i>Hematologia</i> , 2015, 6, 293-300.	0.0	1
98	HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. <i>Blood</i> , 2015, 126, 1436-1436.	0.6	0
99	FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 314-314.	0.6	0
100	Ocena stopnia zaawansowania i odpowiedzi na leczenie u chorych na chłoniaka Hodgkina i chłoniaki nie-Hodgkina – rekomendacje Międzynarodowej Grupy Roboczej z Lugano. <i>Hematologia</i> , 2015, 6, 223-232.	0.0	1
101	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>Blood</i> , 2015, 126, 4917-4917.	0.6	0
102	Quiz. Correct answer to the quiz. Check your diagnosis Hodgkin's lymphoma mimicking tuberculosis in cervical lymph nodes. <i>Polish Journal of Pathology</i> , 2014, 1, 83-88.	0.1	2
103	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 606-610.	0.6	5
104	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective – A report by Polish Myeloma Study Group. <i>Leukemia Research</i> , 2014, 38, 788-794.	0.4	4
105	Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. <i>Cancer Research</i> , 2014, 74, 1749-1749.	0.4	2
106	Hodgkin's lymphoma during pregnancy – case report. <i>Current Gynecologic Oncology</i> , 2014, 12, 67-72.	0.1	0
107	Human Leukocyte Antigen-G Polymorphisms Influence Clinical Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1643-1643.	0.6	0
108	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1642-1642.	0.6	0

#	ARTICLE	IF	CITATIONS
109	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. <i>Blood</i> , 2014, 124, 3641-3641.	0.6	0
110	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 165-174.	1.0	2
111	Polymorphisms of <i>TNF</i> and <i>IL10</i> genes and clinical outcome of patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 287-296.	1.5	28
112	Chłoniak grudkowy: rozpoznawanie i leczenie. <i>Acta Haematologica Polonica</i> , 2013, 44, 171-176.	0.1	0
113	Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. <i>Chemotherapy</i> , 2013, 59, 280-289.	0.8	4
114	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 2860-2860.	0.6	5
115	Purine Analogues Based Induction Regimen Followed By Allo-HSCT Is An Effective Treatment Modality Of Philadelphia Chromosome-Positive Acute Myeloid Leukemia-Retrospective Analysis Of Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2013, 122, 1461-1461.	0.6	0
116	Novel and Emerging Drugs for Acute Lymphoblastic Leukemia. <i>Current Cancer Drug Targets</i> , 2012, 12, 505-521.	0.8	5
117	Serum Tumor Necrosis Factor- $\alpha$ and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 477-486.	1.0	15
118	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.1	5
119	Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis. <i>Blood</i> , 2012, 120, 4602-4602.	0.6	0
120	Novel Systemic Drugs for Cutaneous T-Cell Lymphoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 70-93.	0.8	3
121	Novel Purine Nucleoside Analogues for Hematological Malignancies. , 2011, , 219-240.		0
122	Plasma TNF- $\alpha$ and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	1.0	37
123	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1529-1543.	1.1	19
124	Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). <i>International Journal of Infectious Diseases</i> , 2010, 14, e132-e140.	1.5	33
125	Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1351-1353.	0.6	6
126	The TNF $\alpha$ 308G>A Polymorphism Predicts Outcome of Patients with B-Cell Chronic Lymphocytic Leukemia In Relation to the IgVH Mutation Status. <i>Blood</i> , 2010, 116, 2421-2421.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4467-4467.	0.6	0
128	Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 805-812.	1.1	21
129	Toll-Like Receptors and their Role in Hematologic Malignancies. <i>Current Molecular Medicine</i> , 2009, 9, 324-335.	0.6	27
130	Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. <i>Cellular and Molecular Biology Letters</i> , 2009, 14, 248-72.	2.7	58
131	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	0.6	20
132	PCN88 AN ECONOMIC EVALUATION OF RITUXIMAB VERSUS OTHER FIRST-LINE TREATMENTS FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND. <i>Value in Health</i> , 2009, 12, A273.	0.1	2
133	Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. <i>Molecules</i> , 2009, 14, 1183-1226.	1.7	66
134	Significance of Minimal Residual Disease in Patients with Chronic Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3269-3269.	0.6	0
135	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. <i>Cancer</i> , 2008, 113, 367-375.	2.0	22
136	Novel Purine Nucleoside Analogues for Hematological Malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 123-136.	0.8	23
137	Impact of Interleukin-10 Gene Promoter Polymorphisms on Clinical Course of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4168-4168.	0.6	0
138	Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 1062-1069.	1.1	27
139	Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2235-2238.	0.6	21
140	Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1042-1044.	0.6	5
141	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	0.6	10
142	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 710-711.	1.7	12
143	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma. <i>Journal of Clinical Immunology</i> , 2007, 27, 339-346.	2.0	34
144	Circulating Endothelial Cells as Noninvasive Marker of Angiogenesis in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 1124-1124.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity. <i>Current Medicinal Chemistry</i> , 2006, 13, 3165-3189.	1.2	138
146	Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 575-581.	1.1	30
147	Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. <i>European Cytokine Network</i> , 2006, 17, 60-6.	1.1	53
148	A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. <i>Annals of Hematology</i> , 2005, 84, 557-564.	0.8	40
149	The VH3-21 Gene Status Correlates with Elevated $\hat{\imath}^2$ -Microglobulin Serum Levels and Shorter Overall Survival of Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 4988-4988.	0.6	0
150	Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. <i>Blood</i> , 2004, 103, 3529-3534.	0.6	162
151	A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). <i>European Journal of Haematology</i> , 2003, 71, 155-162.	1.1	52
152	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. <i>Blood</i> , 2002, 100, 3037-3040.	0.6	78
153	Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. <i>European Journal of Haematology</i> , 2001, 66, 188-194.	1.1	30
154	Influence of gemcitabine (2,2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. <i>European Journal of Haematology</i> , 2000, 65, 317-321.	1.1	9
155	Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 121-129.	0.6	54
156	2-Chlorodeoxyadenosine (2-CDA) does not Change the Expression of Fas Antigen on Chronic Lymphocytic Leukaemia Cells. , 2000, 486, 307-310.		0